 CAMBRIDGE, Mass.--BUSINESS WIRE--- AVRO--AVROBIO, Inc. Nasdaq: AVRO, a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced Azadeh Golipour, Ph.D., chief technology officer at AVROBIO, will present virtually at Cowens 2nd Annual Genetic Medicines Summit at 2:00 p.m. ET on Thursday, Feb. 3, 2022. About AVROBIO Our vision is to bring personalized gene therapy to the world. We aim to prevent, halt or reverse disease throu 